Oramed Pharmaceuticals Inc. (ORMP) compared with its closest peers (IMUX, KROS, ANTX, SIGA, PEPG): P/E 3.9 vs industry 17.0. Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Immunic, Inc. (IMUX) | $225.00M | -0.9 |
| Keros Therapeutics, Inc. (KROS) | $219.29M | 8.8 |
| AN2 Therapeutics, Inc. (ANTX) | $218.87M | -1.0 |
| SIGA Technologies, Inc. (SIGA) | $218.76M | 10.8 |
| PepGen Inc. (PEPG) | $216.78M | -3.1 |
| Journey Medical Corporation (DERM) | $213.21M | -16.4 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | $201.15M | -1.4 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | $200.38M | -1.1 |
| Korro Bio, Inc. (KRRO) | $193.49M | -0.6 |
| Nkarta, Inc. (NKTX) | $190.16M | -1.3 |
| Stock P/E | 3.9 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| vs Sector | -81.9% |
| vs Industry | -76.8% |
ORMP overview · ORMP earnings · ORMP financials · ORMP KPIs · ORMP investor relations · ORMP ownership · ORMP filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.